David S. Ege

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Cambridge, MA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Thomas J. DesRosier, attorney-in-fact for David S. Ege
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for David S. Ege

Form 4 holding Executive Vice President and Chief Technology Officer

Seres Therapeutics, Inc.

Security class
Common Stock
Shares / value
77,575
Estimated value
$65,163
Report date
16 Aug 2024
Price
$0.8400
Ownership
Direct
Form 4 holding Executive Vice President and Chief Technology Officer

Seres Therapeutics, Inc.

Security class
Restricted Stock Units
Shares / value
29,688
Estimated value
$32,179
Report date
15 Aug 2024
Price
$1.08
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Executive Vice President and Chief Technology Officer

Seres Therapeutics, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
287,905
Estimated value
Report date
14 Feb 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by David S. Ege

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .